111In-CHxADTPA-trastuzumab (Center for Cancer Research, Leidos Biomedical Research Inc/National Institutes of Health)

N/A

Report date: 2025/11/24 17:27:41

Base Information

Drug Name111In-CHxADTPA-trastuzumab (Center for Cancer Research, Leidos Biomedical Research Inc/National Institutes of Health)

Drug Alias Name[111In]Trastuzumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[7]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsDiagnostic agents

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Institute of Health, Islamabad

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Institutes Of Health

Active IndicationsN/A

Inactive IndicationsDiagnostic agents

Other Information

ATC CodeN/A